CA2869320A1 - Therapeutic uses of fibroblast growth factor 21 variant proteins to increase bone formation or depositions - Google Patents
Therapeutic uses of fibroblast growth factor 21 variant proteins to increase bone formation or depositions Download PDFInfo
- Publication number
- CA2869320A1 CA2869320A1 CA2869320A CA2869320A CA2869320A1 CA 2869320 A1 CA2869320 A1 CA 2869320A1 CA 2869320 A CA2869320 A CA 2869320A CA 2869320 A CA2869320 A CA 2869320A CA 2869320 A1 CA2869320 A1 CA 2869320A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- bone
- fgf21 protein
- fgf21
- provides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title claims abstract description 164
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title claims abstract description 164
- 230000011164 ossification Effects 0.000 title claims description 27
- 230000010256 bone deposition Effects 0.000 title claims description 13
- 108090000623 proteins and genes Proteins 0.000 title abstract description 5
- 102000004169 proteins and genes Human genes 0.000 title abstract description 5
- 230000001225 therapeutic effect Effects 0.000 title abstract description 4
- 238000000151 deposition Methods 0.000 title 1
- 210000000988 bone and bone Anatomy 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 45
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 25
- 239000011707 mineral Substances 0.000 claims description 25
- 206010065687 Bone loss Diseases 0.000 claims description 24
- 208000010392 Bone Fractures Diseases 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 230000008021 deposition Effects 0.000 claims description 16
- 230000024279 bone resorption Effects 0.000 claims description 12
- 206010017076 Fracture Diseases 0.000 claims description 11
- 208000001132 Osteoporosis Diseases 0.000 claims description 11
- 239000004053 dental implant Substances 0.000 claims description 11
- 230000004927 fusion Effects 0.000 claims description 11
- 230000035876 healing Effects 0.000 claims description 11
- 239000007943 implant Substances 0.000 claims description 11
- 208000006386 Bone Resorption Diseases 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 10
- 230000018678 bone mineralization Effects 0.000 claims description 5
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 abstract description 5
- 102000056713 human FGF21 Human genes 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 description 31
- 125000003275 alpha amino acid group Chemical group 0.000 description 30
- 239000003814 drug Substances 0.000 description 30
- 235000010755 mineral Nutrition 0.000 description 21
- 238000011282 treatment Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 241000700159 Rattus Species 0.000 description 13
- 239000000090 biomarker Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 102000004067 Osteocalcin Human genes 0.000 description 8
- 108090000573 Osteocalcin Proteins 0.000 description 8
- 210000000689 upper leg Anatomy 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000010254 subcutaneous injection Methods 0.000 description 6
- 239000007929 subcutaneous injection Substances 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 210000001562 sternum Anatomy 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 229930189065 blasticidin Natural products 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000004190 glucose uptake Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 229960001251 denosumab Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000008227 sterile water for injection Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MYGCFWRBKKQKCG-GBWOLBBFSA-N (z,2r,3s,4r)-hex-5-ene-1,2,3,4,6-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)\C=C/O MYGCFWRBKKQKCG-GBWOLBBFSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 2
- 108700025832 Serum Response Element Proteins 0.000 description 2
- 230000008416 bone turnover Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000003275 diaphysis Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 1
- 101100120063 Homo sapiens FGF21 gene Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000003263 MASS syndrome Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 108010049264 Teriparatide Proteins 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000010258 osteoblastogenesis Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940079488 strontium ranelate Drugs 0.000 description 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261646974P | 2012-05-15 | 2012-05-15 | |
| US61/646,974 | 2012-05-15 | ||
| US201361786939P | 2013-03-15 | 2013-03-15 | |
| US61/786,939 | 2013-03-15 | ||
| PCT/US2013/040275 WO2013173158A1 (en) | 2012-05-15 | 2013-05-09 | Therapeutic uses of fibroblast growth factor 21 proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2869320A1 true CA2869320A1 (en) | 2013-11-21 |
Family
ID=48483225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2869320A Abandoned CA2869320A1 (en) | 2012-05-15 | 2013-05-09 | Therapeutic uses of fibroblast growth factor 21 variant proteins to increase bone formation or depositions |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20150141335A1 (OSRAM) |
| EP (1) | EP2852398A1 (OSRAM) |
| JP (1) | JP2015522539A (OSRAM) |
| KR (1) | KR20150002801A (OSRAM) |
| CN (1) | CN104302311A (OSRAM) |
| AU (1) | AU2013263188A1 (OSRAM) |
| BR (1) | BR112014028413A2 (OSRAM) |
| CA (1) | CA2869320A1 (OSRAM) |
| CL (1) | CL2014002846A1 (OSRAM) |
| CO (1) | CO7131381A2 (OSRAM) |
| EA (1) | EA201491856A1 (OSRAM) |
| HK (1) | HK1202800A1 (OSRAM) |
| IL (1) | IL235482A0 (OSRAM) |
| MA (1) | MA37506B1 (OSRAM) |
| MX (1) | MX2014013913A (OSRAM) |
| PE (1) | PE20142432A1 (OSRAM) |
| PH (1) | PH12014502537A1 (OSRAM) |
| SG (1) | SG11201407655TA (OSRAM) |
| TN (1) | TN2014000409A1 (OSRAM) |
| WO (1) | WO2013173158A1 (OSRAM) |
| ZA (1) | ZA201407532B (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| WO2014085365A2 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| IL292303A (en) | 2012-12-27 | 2022-06-01 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease |
| SG11201602870YA (en) | 2013-10-28 | 2016-05-30 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods |
| PL3097122T3 (pl) | 2014-01-24 | 2020-10-19 | Ngm Biopharmaceuticals, Inc. | Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2016039339A1 (ja) * | 2014-09-08 | 2016-03-17 | 国立大学法人大阪大学 | 脱髄疾患の予防又は治療剤 |
| WO2016065106A1 (en) | 2014-10-23 | 2016-04-28 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| AU2016353988B2 (en) | 2015-11-09 | 2019-09-26 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| WO2018039557A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN108324928B (zh) * | 2018-03-05 | 2020-09-08 | 哈尔滨医科大学 | 重组人成纤维细胞生长因子-5在促骨折愈合中的应用 |
| EP3935075A4 (en) | 2019-03-05 | 2023-01-18 | Sunshine Lake Pharma Co., Ltd. | POLYPEPTIDE MOLECULE AND APPLICATION THEREOF |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| KR20240034235A (ko) | 2021-07-14 | 2024-03-13 | 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 | 대사 장애를 위한 융합 폴리펩타이드 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101476472B1 (ko) * | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| AR087973A1 (es) * | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
-
2013
- 2013-05-09 CA CA2869320A patent/CA2869320A1/en not_active Abandoned
- 2013-05-09 EA EA201491856A patent/EA201491856A1/ru unknown
- 2013-05-09 AU AU2013263188A patent/AU2013263188A1/en not_active Abandoned
- 2013-05-09 EP EP13724685.6A patent/EP2852398A1/en not_active Withdrawn
- 2013-05-09 CN CN201380025338.6A patent/CN104302311A/zh active Pending
- 2013-05-09 WO PCT/US2013/040275 patent/WO2013173158A1/en not_active Ceased
- 2013-05-09 HK HK15103356.5A patent/HK1202800A1/xx unknown
- 2013-05-09 MX MX2014013913A patent/MX2014013913A/es unknown
- 2013-05-09 SG SG11201407655TA patent/SG11201407655TA/en unknown
- 2013-05-09 MA MA37506A patent/MA37506B1/fr unknown
- 2013-05-09 US US14/399,037 patent/US20150141335A1/en not_active Abandoned
- 2013-05-09 PE PE2014001980A patent/PE20142432A1/es not_active Application Discontinuation
- 2013-05-09 KR KR1020147031701A patent/KR20150002801A/ko not_active Withdrawn
- 2013-05-09 BR BR112014028413A patent/BR112014028413A2/pt not_active IP Right Cessation
- 2013-05-09 JP JP2015512695A patent/JP2015522539A/ja not_active Withdrawn
-
2014
- 2014-09-30 TN TNP2014000409A patent/TN2014000409A1/fr unknown
- 2014-10-16 ZA ZA2014/07532A patent/ZA201407532B/en unknown
- 2014-10-22 CL CL2014002846A patent/CL2014002846A1/es unknown
- 2014-11-03 IL IL235482A patent/IL235482A0/en unknown
- 2014-11-14 CO CO14252512A patent/CO7131381A2/es unknown
- 2014-11-14 PH PH12014502537A patent/PH12014502537A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201407532B (en) | 2016-05-25 |
| MX2014013913A (es) | 2015-02-17 |
| JP2015522539A (ja) | 2015-08-06 |
| US20150141335A1 (en) | 2015-05-21 |
| CL2014002846A1 (es) | 2015-01-30 |
| PE20142432A1 (es) | 2015-01-22 |
| TN2014000409A1 (en) | 2015-12-21 |
| PH12014502537A1 (en) | 2015-01-21 |
| SG11201407655TA (en) | 2014-12-30 |
| EA201491856A1 (ru) | 2015-03-31 |
| AU2013263188A1 (en) | 2014-10-16 |
| MA37506B1 (fr) | 2017-03-31 |
| CN104302311A (zh) | 2015-01-21 |
| MA37506A1 (fr) | 2016-01-29 |
| KR20150002801A (ko) | 2015-01-07 |
| WO2013173158A1 (en) | 2013-11-21 |
| BR112014028413A2 (pt) | 2017-11-07 |
| CO7131381A2 (es) | 2014-12-01 |
| HK1202800A1 (en) | 2015-10-09 |
| IL235482A0 (en) | 2014-12-31 |
| EP2852398A1 (en) | 2015-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2852398A1 (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| Van Bezooijen et al. | Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist | |
| Ornitz et al. | Achondroplasia: development, pathogenesis, and therapy | |
| Amizuka et al. | Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. | |
| Duong et al. | Cathepsin K inhibition: a new mechanism for the treatment of osteoporosis | |
| Iwata et al. | Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia | |
| Ballock et al. | Physiology and pathophysiology of the growth plate | |
| Stensen et al. | GIP and the gut-bone axis–physiological, pathophysiological and potential therapeutic implications | |
| Yang et al. | A bone-targeting drug-delivery system based on Semaphorin 3A gene therapy ameliorates bone loss in osteoporotic ovariectomized mice | |
| Sabir et al. | The evolving therapeutic landscape of genetic skeletal disorders | |
| EA016041B1 (ru) | Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта | |
| KR100987731B1 (ko) | 골형성촉진용 합성펩타이드, 상기 합성 펩타이드를 포함하는 약학조성물 및 배지조성물 | |
| Fahmy-Garcia et al. | Follistatin effects in migration, vascularization, and osteogenesis in vitro and bone repair in vivo | |
| Tudpor et al. | Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio | |
| Zhao et al. | CCN1/Cyr61 is required in osteoblasts for responsiveness to the anabolic activity of PTH | |
| Villa et al. | Effects of amylin on human osteoblast-like cells | |
| Conen et al. | The transcriptional cofactor Lbh regulates angiogenesis and endochondral bone formation during fetal bone development | |
| Mentaverri et al. | Potential anti-catabolic and anabolic properties of strontium ranelate | |
| Chen et al. | The influence of the sensory neurotransmitter calcitonin gene-related peptide on bone marrow mesenchymal stem cells from ovariectomized rats | |
| Sekiya et al. | Effects of the bisphosphonate risedronate on osteopenia in OASIS-deficient mice | |
| Mora-Antoinette et al. | Osteocyte Nicotinic Acetylcholine Receptors Impact Bone Mechanoadaptation in a Sexually Dimorphic Manner: Osteocyte Cholinergic Signaling in Mechanoadaptation | |
| JP5116041B2 (ja) | 骨形成促進用合成ペプチド、この合成ペプチドを含む薬学組成物および培地組成物 | |
| CN115105597A (zh) | Kindlin-2作为靶点在治疗骨质疏松及预防癌症骨转移中的应用 | |
| Monsonego et al. | Generation of growth hormone binding protein by avian growth plate chondrocytes is dependent on cell differentiation | |
| AU1110600A (en) | Methods for regulating bone formation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20141001 |
|
| FZDE | Discontinued |
Effective date: 20170510 |